Triple-negative vimentin-positive heterogeneous feline mammary carcinomas as a potential comparative model for breast cancer

BMC Veterinary Research

Volumn 10, Issue 1, 2014, Pages

  Caliari, Diego ^a   Zappulli, Valentina ^a   Rasotto, Roberta ^b   Cardazzo, Barbara ^a   Frassineti, Federica ^a   Goldschmidt, Michael H ^c   Castagnaro, Massimo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b ANIMAL HEALTH TRUST   (United Kingdom)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Feline; Human breast cancer; Mammary tumor; Markers; Triple negative; Vimentin

Indexed keywords

FELIDAE;

CELL SURFACE RECEPTOR; VIMENTIN;

ANIMAL; BREAST TUMOR; CAT; CAT DISEASE; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY;

ANIMALS; BREAST NEOPLASMS; CAT DISEASES; CATS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAMMARY NEOPLASMS, ANIMAL; RECEPTORS, CELL SURFACE; VIMENTIN;

EID: 84910104349     PISSN: None     EISSN: 17466148     Source Type: Journal    
DOI: 10.1186/s12917-014-0185-8     Document Type: Article

References (50)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30. 10.3322/caac.21166, 23335087.
2. Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. 10.1038/nature11412.
3. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011, 5:5-23. 10.1016/j.molonc.2010.11.003, 21147047.
4. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874. 10.1073/pnas.191367098, 11553815.
5. Malhotra GK, Zhao X, Band H, Band V. Histological, molecular and functional subtypes of breast cancers. Cancer Biol Ther 2010, 10:955-960. Review, 10.4161/cbt.10.10.13879, 21057215.
6. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28:2784-2795. 10.1200/JCO.2009.25.6529, 20404251.
7. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Penault-Llorca F, Prudkin L, Regan M, Salter J, Sotiriou C, Smith IE, Viale G, Zujewski JA, Hayes DF. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011, 103:1656-1664. 10.1093/jnci/djr393, 21960707.
8. Matos AJ, Baptista CS, Gärtner MF, Rutteman GR. Prognostic studies of canine and feline mammary tumours: the need for standardized procedures. Vet J 2012, 193:24-31. 10.1016/j.tvjl.2011.12.019, 22296767.
9. Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist 2011, 16(suppl. 1):61-70. 10.1634/theoncologist.2011-S1-61, 21278442.
10. Metzger-Filho O, Tutt A, De Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA, Ellis P, Di Leo A, Baselga J, Sotiriou C, Piccart-Gebhart M. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol 2012, 30:1879-1887. Review, 10.1200/JCO.2011.38.2010, 22454417.
11. Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy?. Nat Rev Clin Oncol 2009, 6:718-730. Review, 10.1038/nrclinonc.2009.166, 19942925.
12. Rakha EA, Elsheikh SE, Aleskandarany MA, Habashi HO, Green AR, Powe DG, El-Sayed ME, Benhasouna A, Brunet JS, Akslen LA, Evans AJ, Blamey R, Reis-Filho JS, Foulkes WD, Ellis IO. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009, 15:2302-2310. 10.1158/1078-0432.CCR-08-2132, 19318481.
13. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 2010, 12(5):R68. 10.1186/bcr2635, 20813035.
14. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ, kConFab, Fox SB, Yan M, French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GJ. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009, 15:907-913. 10.1038/nm.2000, 19648928.
15. Misdorp W, Else RW, Hellmen E, Lipscomb TP. Histological Classification of Mammary Tumours of the Dog and Cat. Armed Forces Institute of Pathology 2001, American Registry of Pathology, Washington DC.
16. Goldschmidt M, Peña L, Rasotto R, Zappulli V. Classification and grading of canine mammary tumors. Vet Pathol 2011, 48:117-131. 10.1177/0300985810393258, 21266722.
17. Brunetti B, Asproni P, Beha G, Muscatello LV, Millanta F, Poli A, Benazzi C, Sarli G. Molecular phenotype in mammary tumours of queens: correlation between primary tumour and lymph node metastasis. J Comp Pathol 2013, 148:206-213. 10.1016/j.jcpa.2012.05.012, 22819018.
18. Burrai GP, Mohammed SI, Miller MA, Marras V, Pirino S, Addis MF, Uzzau S, Antuofermo E. Spontaneous feline mammary intraepithelial lesions as a model for human estrogen receptor- and progesterone receptor-negative breast lesions. BMC Cancer 2010, 10:156. 10.1186/1471-2407-10-156, 20412586.
19. De Maria R, Olivero M, Iussich S, Nakaichi M, Murata T, Biolatti B, Di Renzo MF. Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer. Cancer Res 2005, 65:907-912. 15705889.
20. Millanta F, Calandrella M, Citi S, Della Santa D, Poli A. Overexpression of HER-2 in feline invasive mammary carcinomas: an immunohistochemical survey and evaluation of its prognostic potential. Vet Pathol 2005, 42:30-34. 10.1354/vp.42-1-30, 15657269.
21. Millanta F, Calandrella M, Vannozzi I, Poli A. Steroid hormone receptors in normal, dysplastic and neoplastic feline mammary tissues and their prognostic significance. Vet Rec 2006, 158:821-824. 10.1136/vr.158.24.821, 16782855.
22. Rasotto R, Caliari D, Castagnaro M, Zanetti R, Zappulli V. An immunohistochemical study of HER-2 expression in feline mammary tumours. J Comp Pathol 2011, 144:170-179. 10.1016/j.jcpa.2010.08.010, 20880546.
23. Soares M, Correia J, Rodrigues P, Simões M, De Matos A, Ferreira F. Feline HER2 protein expression levels and gene status in feline mammary carcinoma: optimization of Immunohistochemistry (IHC) and In Situ Hybridization (ISH) Techniques. Microsc Microanal 2013, 30:1-7.
24. Zappulli V, De Cecco S, Trez D, Caliari D, Aresu L, Castagnaro M. Immunohistochemical expression of E-cadherin and β-catenin in feline mammary tumours. J Comp Pathol 2012, 147:161-170. 10.1016/j.jcpa.2012.02.004, 22520821.
25. Peñafiel-Verdu C, Buendia AJ, Navarro JA, Ramirez GA, Vilafranca M, Altimira J, Sanchez J. Reduced expression of E-cadherin and β-catenin and high expression of basal cytokeratins in feline mammary carcinomas with regional metastasis. Vet Pathol 2012, 49:979-987. 10.1177/0300985812436744, 22337774.
26. Martín De Las Mulas J, Reymundo C, Espinosa De Los Monteros A, Millán Y, Ordás J. Calponin expression and myoepithelial cell differentiation in canine, feline and human mammary simple carcinomas. Vet Comp Oncol 2004, 2:24-35. 10.1111/j.1476-5810.2004.00036.x, 19379308.
27. Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 2008, 8:147-156. 10.1038/nrc2273, 18202698.
28. Porrello A, Cardelli P, Spugnini EP. Oncology of companion animals as a model for humans. an overview of tumor histotypes. J Exp Clin Cancer Res 2006, 25:97-105. Review, 16761625.
29. Ranieri G, Gadaleta CD, Patruno R, Zizzo N, Daidone MG, Hansson MG, Paradiso A, Ribatti D. A model of study for human cancer: spontaneous occurring tumors in dogs: biological features and translation for new anticancer therapies. Crit Rev Oncol Hematol 2013, 88(1):187-197. 10.1016/j.critrevonc.2013.03.005, 23561333.
30. Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit all. Nat Rev Cancer 2007, 7:659-672. 10.1038/nrc2193, 17721431.
31. Zappulli V, Caliari D, Rasotto R, Ferro S, Castagnaro M, Goldschmidt M. Proposed classification of the feline complex mammary tumors as ductal and intraductal papillary mammary tumors. Vet Pathol 2013, 50(6):1070-1077. 10.1177/0300985813488894, 23735615.
32. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer: I: the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410. 10.1111/j.1365-2559.1991.tb00229.x, 1757079.
33. Castagnaro M, Casalone C, Bozzetta E, De Maria R, Biolatti B, Caramelli M. Tumour grading and the oneyear post-surgical prognosis in feline mammary carcinomas. J Comp Path 1998, 119:263e275. 10.1016/S0021-9975(98)80049-2.
34. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009, 101:736-750. 10.1093/jnci/djp082, 19436038.
35. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ. Panel members. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011, 22:1736-1747. 10.1093/annonc/mdr304, 21709140.
36. Hammond ME. ASCO-CAP guidelines for breast predictive factor testing: an update. Appl Immunohistochem Mol Morphol 2011, 19:499-500. 10.1097/PAI.0b013e31822a8eac, 22089488.
37. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145. 10.1200/JCO.2006.09.2775, 17159189.
38. Maniscalco L, Iussich S, De Las Mulas JM, Millán Y, Biolatti B, Sasaki N, Nakagawa T, De Maria R. Activation of AKT in feline mammary carcinoma: a new prognostic factor for feline mammary tumours. Vet J 2012, 191:65-71. 10.1016/j.tvjl.2010.12.016, 21282070.
39. Kim TJ, Lee A, Choi YJ, Song BJ, Yim HW, Kang CS. Prognostic significance of high expression of ER-beta in surgically treated ER-positive breast cancer following endocrine therapy. J Breast Cancer 2012, 15:79-86. 10.4048/jbc.2012.15.1.79, 22493632.
40. Ordás J, Millán Y, Dios R, Reymundo C, De Las Mulas JM. Proto-oncogene HER-2 in normal, dysplastic and tumorous feline mammary glands: an immunohistochemical and chromogenic in situ hybridization study. BMC Cancer 2007, 7:179. 10.1186/1471-2407-7-179, 17880730.
41. Selvarajan S, Bay BH, Chng MJ, Tan PH. The HercepTest and routine C-erbB2 immunohistochemistry in breast cancer: any difference?. Ann Acad Med Singap 2004, 33:473-476. 15329759.
42. Martín De Las Mulas J, Espinosa De Los Monteros A, Bautista MJ, Gómez-Villamandos JC, Morales C. Immunohistochemical distribution pattern of intermediate filament proteins and muscle actin in feline and human mammary carcinomas. J Comp Pathol 1994, 111:365-381. 10.1016/S0021-9975(05)80095-7, 7533801.
43. Sarli G, Brunetti B, Benazzi C. Mammary mucinous carcinoma in the cat. Vet Pathol 2006, 43:667-673. 10.1354/vp.43-5-667, 16966443.
44. Green KJ, Bohringer M, Gocken T, Jones JC. Intermediate filament associated proteins. Adv Protein Chem 2005, 70:143-202. 10.1016/S0065-3233(05)70006-1, 15837516.
45. Korsching E, Packeisen J, Liedtke C, Hungermann D, Wülfing P, Van Diest PJ, Brandt B, Boecker W, Buerger H. The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential?. J Pathol 2005, 206:451-457. 10.1002/path.1797, 15906273.
46. Kusinska RU, Kordek R, Pluciennik E, Bednarek AK, Piekarski JH, Potemski P. Does vimentin help to delineate the so-called 'basal type breast cancer'?. J Exp Clin Cancer Res 2009, 28:118. 10.1186/1756-9966-28-118, 19695088.
47. Yamashita N, Tokunaga E, Kitao H, Hisamatsu Y, Taketani K, Akiyoshi S, Okada S, Aishima S, Morita M, Maehara Y. Vimentin as a poor prognostic factor for triple-negative breast cancer. J Cancer Res Clin Oncol 2013, 139:739-746. 10.1007/s00432-013-1376-6, 23354842.
48. Iyer SV, Dange PP, Alam H, Sawant SS, Ingle AD, Borges AM, Shirsat NV, Dalal SN, Vaidya MM. Understanding the role of keratins 8 and 18 in neoplastic potential of breast cancer derived cell lines. PLoS One 2013, 8:e53532. 10.1371/journal.pone.0053532, 23341946.
49. Kasper M, Moll R, Stosiek P, Karsten U. Patterns of cytokeratin and vimentin expression in the human eye. Histochemistry 1988, 89:369-377. 10.1007/BF00500639, 2457569.
50. Pérez-Martínez C, García-Fernández RA, Escudero A, Ferreras MC, García-Iglesias MJ. Expression of cytokeratins and vimentin in normal and neoplastic tissue from the bovine female reproductive tract. J Comp Pathol 2001, 124:70-78. 10.1053/jcpa.2000.0430, 11428191.